Time filter

Source Type

News Article | May 9, 2017
Site: globenewswire.com

OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to announce that  Raphael Mechoulam has agreed to extend his role as an advisor to the Company. Mechoulam is an Israeli Organic Chemist, and a  professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the "Father of Marijuana Research." Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first endogenous cannabinoid, Anandamide, in 1992. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann. “I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies” said Professor Mechoulam. “The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann. ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@abcannglobal.com OR Leo Karabelas by phone (416) 543-3120 or by email at leo.k@abcannglobal.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.


News Article | May 9, 2017
Site: globenewswire.com

OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to announce that  Raphael Mechoulam has agreed to extend his role as an advisor to the Company. Mechoulam is an Israeli Organic Chemist, and a  professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the "Father of Marijuana Research." Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first endogenous cannabinoid, Anandamide, in 1992. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann. “I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies” said Professor Mechoulam. “The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann. ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@abcannglobal.com OR Leo Karabelas by phone (416) 543-3120 or by email at leo.k@abcannglobal.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.


News Article | May 9, 2017
Site: globenewswire.com

OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to announce that  Raphael Mechoulam has agreed to extend his role as an advisor to the Company. Mechoulam is an Israeli Organic Chemist, and a  professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the "Father of Marijuana Research." Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first endogenous cannabinoid, Anandamide, in 1992. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann. “I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies” said Professor Mechoulam. “The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann. ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@abcannglobal.com OR Leo Karabelas by phone (416) 543-3120 or by email at leo.k@abcannglobal.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.


News Article | May 9, 2017
Site: globenewswire.com

OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to announce that  Raphael Mechoulam has agreed to extend his role as an advisor to the Company. Mechoulam is an Israeli Organic Chemist, and a  professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the "Father of Marijuana Research." Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first endogenous cannabinoid, Anandamide, in 1992. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann. “I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies” said Professor Mechoulam. “The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann. ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@abcannglobal.com OR Leo Karabelas by phone (416) 543-3120 or by email at leo.k@abcannglobal.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.


News Article | May 9, 2017
Site: globenewswire.com

OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to announce that  Raphael Mechoulam has agreed to extend his role as an advisor to the Company. Mechoulam is an Israeli Organic Chemist, and a  professor at the Hebrew University of Jerusalem’s Medical Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the "Father of Marijuana Research." Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first endogenous cannabinoid, Anandamide, in 1992. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this, says Aaron Keay CEO and Director of ABcann. “I have followed the development of cannabis for medical use for many years. There is no doubt that it is very helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical industry and the regulatory agencies” said Professor Mechoulam. “The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann. ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@abcannglobal.com OR Leo Karabelas by phone (416) 543-3120 or by email at leo.k@abcannglobal.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.


Merquiol E.,Hebrew University of Jerusalem | Uzi D.,Hebrew University of Jerusalem | Mueller T.,Charité - Medical University of Berlin | Goldenberg D.,Hebrew University of Jerusalem | And 4 more authors.
PLoS ONE | Year: 2011

Background: The endoplasmic reticulum (ER) is the cellular site for protein folding. ER stress occurs when protein folding capacity is exceeded. This stress induces a cyto-protective signaling cascades termed the unfolded protein response (UPR) aimed at restoring homeostasis. While acute ER stress is lethal, chronic sub-lethal ER stress causes cells to adapt by attenuation of UPR activation. Hepatitis C virus (HCV), a major human pathogen, was shown to cause ER stress, however it is unclear whether HCV induces chronic ER stress, and if so whether adaptation mechanisms are initiated. We wanted to characterize the kinetics of HCV-induced ER stress during infection and assess adaptation mechanisms and their significance. Methods and Findings: The HuH7.5.1 cellular system and HCV-transgenic (HCV-Tg) mice were used to characterize HCV-induced ER stress/UPR pathway activation and adaptation. HCV induced a wave of acute ER stress peaking 2-5 days post-infection, which rapidly subsided thereafter. UPR pathways were activated including IRE1 and EIF2α phosphorylation, ATF6 cleavage and XBP-1 splicing. Downstream target genes including GADD34, ERdj4, p58ipk, ATF3 and ATF4 were upregulated. CHOP, a UPR regulated protein was activated and translocated to the nucleus. Remarkably, UPR activity did not return to baseline but remained elevated for up to 14 days post infection suggesting that chronic ER stress is induced. At this time, cells adapted to ER stress and were less responsive to further drug-induced ER stress. Similar results were obtained in HCV-Tg mice. Suppression of HCV by Interferon-α 2a treatment, restored UPR responsiveness to ER stress tolerant cells. Conclusions: Our study shows, for the first time, that HCV induces adaptation to chronic ER stress which was reversed upon viral suppression. These finding represent a novel viral mechanism to manipulate cellular response pathways. © 2011 Merquiol et al.


Bandgar B.P.,University of Solapur | Bandgar B.P.,Swami Ramanand Teerth Marathwada University | Gawande S.S.,Swami Ramanand Teerth Marathwada University | Warangkar S.C.,Swami Ramanand Teerth Marathwada University | Totre J.V.,Institute for Drug Research
Bioorganic and Medicinal Chemistry | Year: 2010

An efficient solvent-free procedure for the synthesis of thiomorpholides in the presence of a catalytic amount of solid-supported fluoroboric acid (HBF4-SiO2) is described. The advantages of this method are high yields, short reaction times, ease of product isolation, low cost, and the catalyst can be recycled for a number of times without significant loss of activity. Three thiomorpholides possessing electron-donating group (4c, 4g, and 4h) were exhibiting excellent stimulatory activities against Erwinia carotovora l-asparaginase. The most potent activator, compound 4h displayed the following kinetic parameters, Km = 75 μM and Vmax = 1000 μmol mg-1 min-1 and KA = 0.985 μM. Furthermore, these compounds (4g, 4h, 4c, 4f, 4a, and 4d) have also shown promising 2,2′-diphenyl-1-picrylhydrazyl (DPPH) reducing antioxidant activity (21-36%) at 1 mM concentration as compared to standard butylated hydroxyl anisole (72% at 1 mM). © 2010.


Bandgar B.P.,University of Solapur | Bandgar B.P.,Swami Ramanand Teerth Marathwada University | Gawande S.S.,Swami Ramanand Teerth Marathwada University | Bodade R.G.,Swami Ramanand Teerth Marathwada University | And 2 more authors.
Bioorganic and Medicinal Chemistry | Year: 2010

Chalcones have been identified as interesting compounds with cytotoxicity, anti-inflammatory and antioxidant properties. In the present study, simple methoxychalcones were synthesized by Claisen-Schmidt condensation reaction and evaluated for above biological activities. The structures of the compounds were established by IR, 1H NMR and mass spectral analysis. The data revealed that compound 3s (99-100% at 10 μM concentration) completely inhibit the selected five human cancer cell lines as compared to standard flavopiridol and gemcitabine (70-90% at 700 nM and 500 nM concentrations, respectively), followed by 3a, 3n, 3o, 3p, 3q, 3r. Among the tested compounds 3l, 3m, 3r, and 3s exhibited promising anti-inflammatory activity against TNF-α and IL-6 with 90-100% inhibition at 10 μM concentration. DPPH free radical scavenging activity was given by the compounds 3o, 3n, 3l, 3r, 3m, 3a, 3p, 3c and 3s at 1 mM concentration. Overall, 3s was obtained as lead compound with promising anticancer, anti-inflammatory and antioxidant activities. Bioavailability of compounds were checked by in vitro cytotoxicity study and confirmed to be nontoxic. The structure activity relationship (SAR) and in silico drug relevant properties (HBDs, HBAs, PSA, c Log P, ionization potential, molecular weight, EHOMO and ELUMO) further confirmed that the compounds were potential candidates for future drug discovery study. © 2009 Elsevier Ltd. All rights reserved.


Amit-Avraham I.,Institute for Medical Research Israel Canada | Pozner G.,Institute for Medical Research Israel Canada | Eshar S.,Institute for Medical Research Israel Canada | Fastman Y.,Institute for Medical Research Israel Canada | And 3 more authors.
Proceedings of the National Academy of Sciences of the United States of America | Year: 2015

The virulence of Plasmodium falciparum, the causative agent of the deadliest form of human malaria, is attributed to its ability to evade human immunity through antigenic variation. These parasites alternate between expression ofvariable antigens, encoded by members of a multicopy gene family named var. Immune evasion through antigenic variation depends on tight regulation of var gene expression, ensuring that only a single var gene is expressed at a time while the rest of the family is maintained transcriptionally silent. Understanding how a single gene is chosen for activation is critical for understanding mutually exclusive expression but remains a mystery. Here, we show that antisense long noncoding RNAs (lncRNAs) initiating from var introns are associated with the single active var gene at the time in the cell cycle when the single var upstream promoter is active. We demonstrate that these antisense transcripts are incorporated into chromatin, and that expression of these antisense lncRNAs in trans triggers activation of a silent var gene in a sequence- and dose-dependent manner. On the other hand, interference with these lncRNAs using complement peptide nucleic acid molecules down-regulated the active var gene, erased the epigenetic memory, and induced expression switching. Altogether, our data provide evidence that these antisense lncRNAs play a key role in regulating var gene activation and mutually exclusive expression.


Nordling-David M.M.,Institute for Drug Research | Golomb G.,Institute for Drug Research
Israel Journal of Chemistry | Year: 2013

In gene therapy, genetic materials, such as plasmid DNA, antisense oligonucleotides (asODNs), and small interfering RNA (siRNA), can be used to treat or prevent disease. This includes replacing a mutated gene, inactivating a mutated gene, or introducing a new gene. Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), successful gene therapy is hampered by the lack of effective delivery systems (viral and nonviral). There are several nonviral gene carriers, such as lipids, polymers, and peptides, that can be used for this purpose. Liposomal delivery of nucleic acids, such as plasmid DNA, asODNs, and siRNAs, represents a very promising nanocarrier system that is relatively safe and effective in delivering genes to targeted locations in the body. Lipoidbased delivery systems have also been shown to be stable in serum and plasma, have improved biodistribution, prolonged circulation half-life, and enhanced target tissue selectivity. The most common lipids used in liposomes are cationic lipids, which facilitate binding between their positively charged head group(s) to negatively charged nucleic acids. This review is focused on the most common methods of lipoid-based nanocarriers of nucleic acids for gene therapy in vivo. © 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Loading Institute for Drug Research collaborators
Loading Institute for Drug Research collaborators